Tofacitinib as an adjuvant treatment for pediatric Still's disease

Area of Science:

• Rheumatology
• Pediatric Immunology
• Pharmacology

Background:

• Pediatric Still's disease, or systemic-onset juvenile idiopathic arthritis (sJIA), has limited treatment options beyond traditional non-biologics and cytokine-targeted therapies.
• Some patients with sJIA exhibit inadequate responses to existing treatments, necessitating novel therapeutic approaches.

Purpose of the Study:

• To evaluate the efficacy and safety of tofacitinib in pediatric patients diagnosed with Still's disease/sJIA.
• To assess tofacitinib's impact on corticosteroid use, concurrent medication needs, and overall disease control in this population.

Main Methods:

• Retrospective analysis of ten pediatric patients with Still's disease treated with tofacitinib.
• Collection and review of patient data including medical history, laboratory results, and treatment regimens at various disease stages.

Main Results:

• Tofacitinib induced complete remission in 60% (6/10) and partial remission in 30% (3/10) of patients.
• Remission was associated with significant reductions in corticosteroid dosage and concurrent medication requirements.
• Tofacitinib was well-tolerated, with a low incidence of adverse events, and improved outcomes for patients previously treated with tocilizumab.

Conclusions:

• Tofacitinib shows significant promise as an effective adjunctive therapy for pediatric Still's disease/sJIA.
• It is particularly beneficial for patients with challenging clinical presentations or those experiencing adverse effects from corticosteroids.
• The drug's favorable safety profile supports its consideration in refractory sJIA cases.